SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Nissan Plans Major Lineup Cuts and AI Expansion in Bid for Global Sales Recovery 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
United Airlines Eyes Merger with American Airlines in Potential Industry-Shaping Deal 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Daewoong Pharmaceuticals struck a deal with Zydus Worldwide DMCC to co-develop anti-cancer injectables in the United States. For this tie-up, the companies signed an agreement worth $92 million.
Korea’s Daewoong and UAE-based Zydus Group aim to market Leuprolide acetate through their licensing deal for the development of a generic of Lupron Depot drug, a leuprolide acetate for depot suspension, that is used for the treatment of advanced prostate cancer, uterine fibroids, and endometriosis. As per The Korea Herald, the former announced its exclusive licensing contract with the latter on Monday, Dec. 11.
Terms of the Deal: Division of Responsibilities
It was stipulated in the agreement that Daewoong would be in charge of preclinical research, studies, production, and supply of the generic called the DWJ108U. The Korean firm shared that it will manufacture the drug at its production plant in Osong, located in North Chungcheong Province.
On the other hand, Zydus will be responsible for all clinical trials and the commercialization of the DWJ108U in the U.S. “Together with Zydus, Daewoong Pharmaceutical will aim to develop and commercialize a generic of AbbVie’s Lupron Depot in the U.S. market,” an official of the Korean pharma company said in a statement.
Contract Period and Payment Agreement
Korea BioMedical Review reported that Daewoong and Zydus agreed to work together for seven years following the first sale. The total value of the licensing deal is about $92.4 million, which will be paid in various forms, including $25.5 million in a commercialization milestone payment and the remaining $66.9 million to be settled soon after the drug’s possible launch in the U.S. market.
Jeon Seng Ho, Daewoong Pharmaceutical’s chief executive officer, said, “Given the complexity, complex generic drug products like Lupron Depot do not exist to date, and we aim to be the first company to manufacture the generic version of this complex, long-acting injectable Lupron Depot product.”
Lastly, Zydus Lifesciences’ managing director, Sharvil Patel, added, “This is an important milestone and we are happy to work with Daewoong for the generic version of Lupron Depot.”
Photo by: Zydus Life Media Kit
